Topical verapamil in glaucoma filtration surgery

Area of Science:

• Ophthalmology
• Pharmacology
• Surgical Research

Background:

• Glaucoma filtration surgery aims to reduce intraocular pressure.
• Verapamil, a calcium-channel blocker, has shown antifibroblastic effects.
• The potential benefit of topical verapamil as an adjunct in glaucoma surgery is unexplored.

Purpose of the Study:

• To investigate the efficacy of adjunctive topical verapamil in patients undergoing glaucoma filtration surgery.
• To determine if verapamil can enhance surgical outcomes and reduce fibrosis.

Main Methods:

• A prospective, double-masked, randomized study involving 56 eyes of 56 patients with chronic open-angle glaucoma.
• Patients underwent trabeculectomy, trabeculectomy with cataract surgery, or Molteno drainage device implantation.
• Postoperative treatment included topical verapamil (0.25%) or placebo for one month, alongside standard corticosteroid and antibiotic regimens.

Main Results:

• No significant differences in preoperative intraocular pressure, medication use, or glaucoma severity were observed between groups.
• Filtration success rates, intraocular pressure, and medication needs were similar between verapamil and placebo groups at all postoperative follow-up points (1 day to 6 months).
• Statistical analysis showed no significant benefit (P > 0.05) for adjunctive topical verapamil.

Conclusions:

• Adjunctive topical verapamil offers no significant benefit when used after glaucoma filtration surgeries.
• The antifibroblastic properties of verapamil did not translate to improved surgical outcomes in this context.
• Further research may be needed to explore other antifibrotic agents or different administration methods.